/ Precision Minute: Your ROS1 & ALK+ NSCLC Questions, Answered
Your ROS1, ALK+ NSCLC Questions, Answered
We’re honored to host Dr. Stephen V. Liu, MD, an Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center of Georgetown University. In Chapter 1 of the Precision Minute series, Dr. Liu explains how targeted therapy works in treating non-small cell lung cancer.
More from Dr. Stephen V. Liu
In this video, we hear from Dr. Stephen V. Liu, a thoracic oncologist at Georgetown...
What lifestyle factors should you be incorporating into your treatment plan? In Chapter 3 of...
You’ve likely come across the terms “duration of response” and “progression-free survival” through your care...
With some new changes to the NCCN Guidelines® for Non-Small Cell Lung Cancer (NSCLC) that...
In Chapter 2 of “Precision Minute,” Dr. Stephen V. Liu, Associate Professor of Medicine, Director...
Is it possible for your non-small cell lung cancer to be ALK-positive and have a...
Testing for ROS1 fusions in non-small cell lung cancer (NSCLC) is essential for identifying patients...
What does it mean to have ALK-positive lung cancer, and why does it matter for...
Neither Outcomes4Me nor any participants in or contributors to any webinar, article or content endorses or recommends any products or services. Consult your physician regarding any treatment or therapy.
